COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT05605093

Cavan Reilly, PhD

cavanr@biostat.umn.edu

2022-11-04

Recruiting

RCT

Randomized

Parallel

Blind label

multi-center

Treatment

inclusion criteria: age ≥18 years. informed consent for trial participation. hospital admission (or boarding in an emergency department or other area awaiting hospital admission) with signs and/or symptoms of a respiratory infection. confirmation of sars-cov2 infection by nucleic acid test (nat) or equivalent non- nat test [list of approved tests is in the pim] collected within the prior 14 days. onset of symptoms attributable to sars-cov2 infection occurred within 14 days before randomization. hospitalized for the management of covid-19, with signs and/or symptoms suggestive of lower respiratory tract infection.

the patient is expected to be discharged from the hospital within the next 24 hours. medical condition other than the acute respiratory infection (and its manifestations) that is likely to result in death within 7 days of randomization. use of a strong cyp3a inducer within 14 days prior to enrollment moribund condition, defined as prior cardiac arrest during this hospitalization and life expectancy less than 48 hours of randomization. patient undergoing comfort care measures only such that treatment focuses on end-of- life symptom management over prolongation of life. expected inability or unwillingness to participate in study procedures. in the opinion of the investigator, participation in a trial is not in the best interest of the patient. allergy to investigational agent or vehicle use of a concomitant medication that is contraindicated due to a drug-drug interaction with s-217622 moderate to severe hepatic impairment (i.e., child-pugh class b or c) or acute liver failure. known estimated glomerular filtration rate (egrf) <30 ml/min/1.73m 2 continuous renal replacement therapy or chronic dialysis current pregnancy current breastfeeding and unwillingness to defer breastfeeding for 30 days after the last dose of investigational agent. women of child-bearing potential who are unwilling to abstain from sexual intercourse with men or practice appropriate contraception through 30 days from the last dose of the investigational agent. men who are unwilling to abstain from sexual intercourse with women of child- bearing potential or to use barrier contraception through 30 days from the last dose of the investigational agent. inability to take investigational agent in tablet form by mouth.

2

University of Minnesota

18

100

Argentina;Australia;Brazil;Denmark;Georgia;Germany;Greece;Japan;Republic of Korea;Nigeria;Puerto Rico;Singapore;South Africa;Spain;Thailand;Uganda;Ukraine;United Kingdom;United States

Moderate disease at enrollment

3: Moderate disease at enrollment

1500

Days to Recovery Scale assessed over 60 days (DRS-60)

None

Phase 3

[{"arm_notes": "nan", "treatment_id": 1812, "treatment_name": "S-217622", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "nan", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]